On Tuesday, May 13, Vertex met in Toronto with the Health Ministers from Alberta and
\nthe Yukon as part of our ongoing discussions regarding the public reimbursement of
\nKALYDECO in Canada.<\/p>\n
\u201cWhile we had a lengthy discussion, we have not yet reached an agreement with the
\nprovincial and territorial governments, despite the fact that our proposal is as good as or
\nbetter than the agreements in place in 15 countries around the world where people with
\nCF are receiving the medicine through public reimbursement,\u201d said Stuart Arbuckle,
\nExecutive Vice President and Chief Commercial Officer for Vertex. \u201cWe are extremely
\ndisappointed that today\u2019s meeting did not result in an agreement to allow the eligible
\nchildren and adults with CF in Canada to receive this medicine through public
\nreimbursement. People with CF are still waiting for access to KALYDECO, and this
\nprocess is taking much longer than they expect and deserve.\u201d<\/p>\n
Based on the meeting, both parties have committed to further discussions this week.<\/p>\n
In Canada, we continue to provide KALYDECO at no charge to people with CF who are
\nvery sick as part of a compassionate use or expanded access program while we wait for
\nprovincial and territorial governments to make a decision regarding public
\nreimbursement. Vertex will continue to provide the medicine to these patients while
\nreimbursement discussions are ongoing. Further, for the patients receiving KALYDECO
\nunder private insurance in Canada, Vertex will continue to provide patient support
\nservices, including financial assistance to eligible patients who need it.<\/p>\n
KALYDECO was approved by Health Canada in November 2012.<\/p>\n","protected":false},"excerpt":{"rendered":"
On Tuesday, May 13, Vertex met in Toronto with the Health Ministers from Alberta and the Yukon as part of our ongoing discussions regarding the public reimbursement of KALYDECO in Canada. \u201cWhile we had a lengthy discussion, we have not … Continue reading